The Microbiome, Probiotics, and IBS | Exploring the evidence

Key highlights:

• IBS affects up to 10% of people globally, with emerging evidence pointing to the gut microbiome as a key contributor to its pathophysiology.
• Individuals with IBS often exhibit reduced microbial diversity and imbalances in beneficial versus pathogenic bacteria.
• Post-infectious IBS can occur following acute gastroenteritis, with probiotics offering potential benefit, especially early in recovery.
• Multi-strain probiotics like Lab4 have shown significant improvements in IBS symptoms, bowel habits, and emotional wellbeing.
• Psychobiotics targeting the gut-brain axis may support both digestive and mental health in IBS patients.

Read on to explore the growing body of evidence linking gut microbiome modulation to improved outcomes in IBS management.